Sugi Predict

Sugi Predict / Compounds / SCHEMBL304693

SCHEMBL304693

SCHEMBL304693

COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(C(=O)Nc2ccc(C(=O)O)cn2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ GCK P35557 20/20 1.00
▸ RARA P10276 1/20 1.00
▸ RARB P10826 1/20 1.00
▸ RARG P13631 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2667703 1.00 GCK (1.00) GCKRARARARBRARG
SCHEMBL29434815 1.00 GCK (1.00) GCKRARARARBRARG
SCHEMBL29433060 1.00 GCK (1.00) GCKRARARARBRARG
SCHEMBL5435282 0.93 GCK (0.88) GCKRARARARBRARG
SCHEMBL5443877 0.93 GCK (0.86) GCKRARARARBRARG
SCHEMBL5431822 0.92 GCK (0.85) GCKRARARARBRARG
SCHEMBL5441867 0.92 GCK (1.00) GCKRARARARBRARG
SCHEMBL2666479 0.91 GCK (1.00) GCKRARARARBRARG
SCHEMBL14505826 0.91 GCK (1.00) GCKRARARARBRARG
SCHEMBL2666480 0.91 GCK (1.00) GCKRARARARBRARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070078168-A1 PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS ASTRAZENECA AB (SE) 2007-04-05 — — US claimed
CN-111491631-B Active agent 伦敦玛丽女王大学 2024-06-11 — — CN disclosed
US-11690841-B2 Glycolysis-activating agents for treatment or prevention of disease QUEEN MARY UNIVERSITY OF LONDON (GB) 2023-07-04 — — US disclosed
US-11690841-B2 Glycolysis-activating agents for treatment or prevention of disease QUEEN MARY UNIVERSITY OF LONDON (GB) 2023-07-04 — — US disclosed
US-11690841-B2 Glycolysis-activating agents for treatment or prevention of disease QUEEN MARY UNIVERSITY OF LONDON (GB) 2023-07-04 — — US disclosed
CN-109715637-B Glucokinase activators and methods of use thereof 百时美施贵宝公司 2022-04-05 — — CN disclosed
US-20200268750-A1 AGENT QUEEN MARY UNIVERSITY OF LONDON (GB) 2020-08-27 — — US disclosed
US-20200268750-A1 AGENT QUEEN MARY UNIVERSITY OF LONDON (GB) 2020-08-27 — — US disclosed
CN-111491631-A Active agent 伦敦玛丽女王大学 2020-08-04 — — CN disclosed
EP-3681496-A1 AGENT Queen Mary University of London (GB) 2020-07-22 — — EP disclosed
US-7928230-B2 Method for modulating GPR119 G protein-coupled receptor and selected compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2011-04-19 — — US disclosed
US-7910583-B2 [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-22 — — US disclosed
US-20090042919-A1 METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2009-02-12 — — US disclosed
US-20090023702-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2009-01-22 — — US disclosed
US-20090018055-A1 [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2009-01-15 — — US disclosed
US-20080293690-A1 [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2008-11-27 — — US disclosed
US-20070078168-A1 PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS ASTRAZENECA AB (SE) 2007-04-05 — — US disclosed
US-20070078168-A1 PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS ASTRAZENECA AB (SE) 2007-04-05 — — US disclosed
US-20070078168-A1 PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS ASTRAZENECA AB (SE) 2007-04-05 — — US disclosed
WO-2005044801-A1 PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS ASTRAZENECA AB (SE) 2005-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018055-A1 [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS GPR119, GPR139, GPR4 GCK 798/4885RARA 642/4885RARB 545/4885
US-20090042919-A1 METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS GPR119, GPR65, GPR84 GCK 1204/4885RARA 824/4885RARB 516/4885
US-20070078168-A1 PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS GCK, GCKR, GALK1 GCK 1/4885RARA 2455/4885RARB 2687/4885
US-20080293690-A1 [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS GPR119, GPR6, GPR139 GCK 884/4885RARA 574/4885RARB 534/4885
US-20200268750-A1 AGENT NFATC1, CX3CR1, CD47 GCK 35/4885RARA 1979/4885RARB 1677/4885
US-11690841-B2 Glycolysis-activating agents for treatment or prevention of disease HK2, PDK1, HK1 GCK 13/4885RARA 1768/4885RARB 1593/4885
US-20090023702-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS GPR119, GPR65, GPR27 GCK 907/4885RARA 564/4885RARB 451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.